AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3551551 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole 384 mg for 7 nights
Number of subjects: 62
Study 3551551 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 nights
Number of subjects: 62
Study 30924492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 0
Study 30924492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29079379 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg
Number of subjects: 329
Study 29079379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 27616196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 37.5 mg
Number of subjects: 2148
Study 27616196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg
Number of subjects: 2148
Study 27616196 — intervention group
Group type: COMPARATOR
Intervention: Lebrikizumab (both doses)
Number of subjects: 2148
Study 24135768 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of daily isoniazid preventive therapy (IPT)
Number of subjects: 82
Study 24135768 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 82
Study 24135768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IPT and Observation
Number of subjects: 82
Study 21414109 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic prescribing system
Number of subjects: 26
Study 21414109 — intervention group
Group type: COMPARATOR
Intervention: Control (no electronic prescribing system)
Number of subjects: 26
Study 20697947 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention enema with Huchang Jiedu Decoction (HJD), once every day for 3 weeks
Number of subjects: 60
Study 20697947 — intervention group
Group type: COMPARATOR
Intervention: Conventional integrative medicine
Number of subjects: 60
Study 17654087 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 selected male and female trisyllabic Taiwan Mandarin words
Number of subjects: 20
Study 17654087 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar trisyllabic words recorded at 14 intensity levels (‐10 to 16 dB HL)
Number of subjects: 20
Study 15808031 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 63
Study 15808031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 63
Study 15808031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 63
Study 15808031 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63
Study 15808031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 12480010 — intervention group
Group type: EXPERIMENTAL
Intervention: Toomey™ syringe after gastric insufflation
Number of subjects: 0
Study 12480010 — intervention group
Group type: COMPARATOR
Intervention: Toomey™ syringe before gastric insufflation
Number of subjects: 0
Study 10417749 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel 100 microg/g once daily
Number of subjects: 124
Study 10417749 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel 300 microg/g once daily
Number of subjects: 124
Study 10417749 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel 100 microg/g twice daily
Number of subjects: 124
Study 10417749 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (sodium carboxymethylcellulose)
Number of subjects: 124
Study 7496281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (6 to 16 sessions)
Number of subjects: 79
Study 2107830 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐carnitine supplemented formula (600 nmol/ml, for 7 days)
Number of subjects: 29
Study 2107830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplementation)
Number of subjects: 29
Study 540521 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthinol nicotinate (2400 mg daily for 10 weeks)
Number of subjects: 16
Study 540521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 tablets daily for 10 weeks)
Number of subjects: 16
Study 29971469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E vaginal suppository
Number of subjects: 52
Study 29971469 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 52
Study 28019010 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib 50 mg (renal impairment study)
Number of subjects: 56
Study 28019010 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib (20-50 mg depending on liver dysfunction) (hepatic impairment study)
Number of subjects: 56
Study 28019010 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib (before dialysis)
Number of subjects: 56
Study 28019010 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib (after dialysis)
Number of subjects: 56
Study 28019010 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (both studies)
Number of subjects: 56
Study 26448616 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination/selective oropharyngeal decontamination
Number of subjects: 557
Study 26448616 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 557
Study 26448616 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem exposure
Number of subjects: 557
Study 26448616 — intervention group
Group type: EXPERIMENTAL
Intervention: P. aeruginosa
Number of subjects: 557
Study 26448616 — intervention group
Group type: EXPERIMENTAL
Intervention: Klebsiella species
Number of subjects: 557
Study 26448616 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterobacter species
Number of subjects: 557
Study 24040948 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED (stem cells from human exfoliated deciduous teeth)
Number of subjects: 18
Study 24040948 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 21479690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative epidural analgesia (EA)
Number of subjects: 35
Study 21479690 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (IA)
Number of subjects: 35
Study 19817194 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy and horizontal bar exercise
Number of subjects: 120
Study 19817194 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 120
Study 17710800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and yixin jiangya Capsules
Number of subjects: 93
Study 17710800 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (Control)
Number of subjects: 93
Study 15125121 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of nasal salmon calcitonin daily for three months
Number of subjects: 50
Study 15125121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11246059 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MC)
Number of subjects: 70
Study 11246059 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 70
Study 10181020 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (intervention with classroom program, involvement of parents, and teacher courses)
Number of subjects: 4441
Study 10181020 — intervention group
Group type: COMPARATOR
Intervention: Group A (control)
Number of subjects: 4441
Study 10181020 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (intervention without teacher courses)
Number of subjects: 4441
Study 10181020 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (intervention without parental involvement)
Number of subjects: 4441
Study 10181020 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (most extensive intervention) among high-risk students
Number of subjects: 4441
Study 7512100 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (6 to 10 mg/day for 43 days)
Number of subjects: 9
Study 7512100 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 9
Study 2411026 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative X-ray irradiation
Number of subjects: 47
Study 30925783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at an active workstation
Number of subjects: 37
Study 29714449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MF) for 4 weeks
Number of subjects: 41
Study 29714449 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (SP) and desloratadine
Number of subjects: 41
Study 27333970 — intervention group
Group type: EXPERIMENTAL
Intervention: AP with exercise dosing adjustment (APX)
Number of subjects: 21
Study 27333970 — intervention group
Group type: COMPARATOR
Intervention: AP with no exercise dosing adjustment (APN)
Number of subjects: 21
Study 27333970 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (SAP)
Number of subjects: 21
Study 25042878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + chemoradiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel
Number of subjects: 87
Study 25042878 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH-positive disease
Number of subjects: 87
Study 22750403 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35mg once a week for 4 years
Number of subjects: 218
Study 22750403 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35mg once a week for 2 years (former placebo group)
Number of subjects: 218
Study 22750403 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35mg once a week for 2 years
Number of subjects: 218
Study 19967577 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 150
Study 19967577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 150
Study 19967577 — intervention group
Group type: COMPARATOR
Intervention: No-treatment wait-list control
Number of subjects: 150
Study 17387227 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention
Number of subjects: 60
Study 17387227 — intervention group
Group type: COMPARATOR
Intervention: Control (education session)
Number of subjects: 60
Study 17327307 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.d.)
Number of subjects: 100
Study 17327307 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose oral contraceptive (OCP) 35 microg ethinyl estradiol [EE]/2 mg cyproterone acetate
Number of subjects: 100
Study 17327307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OCP (20 microg EE/100 microg levonorgestrel + aldactone 50 mg b.d.)
Number of subjects: 100
Study 15116060 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 80 mg/d
Number of subjects: 6
Study 15116060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10740327 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate
Number of subjects: 51
Study 10740327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8608881 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily after H. pylori eradication
Number of subjects: 33
Study 8608881 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily before H. pylori eradication
Number of subjects: 33
Study 8608881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline intragastric pH before and after H. pylori eradication
Number of subjects: 33
Study 15374410 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 60 mg
Number of subjects: 0
Study 15374410 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg
Number of subjects: 0
Study 15374410 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 100 mg
Number of subjects: 0
Study 15374410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2931964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg t.i.d. for 3 months)
Number of subjects: 110
Study 2931964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (subacute treatment)
Number of subjects: 110
Study 2931964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31588356 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography guided anesthesia
Number of subjects: 1200
Study 31588356 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic practice
Number of subjects: 1200
Study 29051176 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-located welfare advice
Number of subjects: 17
Study 25373688 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT irradiation (test group)
Number of subjects: 32
Study 25373688 — intervention group
Group type: COMPARATOR
Intervention: LLLT sham (control group)
Number of subjects: 32
Study 23392075 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine with 500 mL of diluent
Number of subjects: 43
Study 23392075 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine with 250 mL of diluent
Number of subjects: 43
Study 23392075 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine concentration ≤0.40 mg/mL
Number of subjects: 43
Study 23392075 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine concentration 0.41-0.60 mg/mL
Number of subjects: 43
Study 23392075 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine concentration >0.60 mg/mL
Number of subjects: 43
Study 21472754 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy designed to alter non-weight related self-cognitions
Number of subjects: 69
Study 21472754 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69
Study 19325050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-on-top treatment (OT): 4 g of high-oleic-acid rapeseed oil (4.6 ml, 36 kcal) infused after a fat-free liquid meal (LM, 325 ml, 145 kcal)
Number of subjects: 6
Study 19325050 — intervention group
Group type: COMPARATOR
Intervention: Emulsion treatment (EM): 4 g of labeled rapeseed oil incorporated into LM (325 ml, 181 kcal); 4.6 ml of saline infused as control
Number of subjects: 6
Study 17229483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 86
Study 17229483 — intervention group
Group type: COMPARATOR
Intervention: SPA therapy (ST)
Number of subjects: 86
Study 15041619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mA
Number of subjects: 59
Study 15041619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mA
Number of subjects: 59
Study 11344395 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally available, inexpensive market soap and methylated spirit
Number of subjects: 200
Study 11344395 — intervention group
Group type: COMPARATOR
Intervention: Imported Povidone-iodine (PI)
Number of subjects: 200
Study 9149172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer therapy with fast inhalation at a respiratory rate of 36 breaths/minute and intermittent vocalization
Number of subjects: 0
Study 9149172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer therapy with fast inhalation at a respiratory rate of 36 breaths/minute
Number of subjects: 0
Study 9149172 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic nebulizer therapy with deep and slow inhalation at a respiratory rate of 12 breaths/minute
Number of subjects: 0
Study 8120152 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 153
Study 8120152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 8120152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 153
Study 3661285 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 0
Study 31848062 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled N-acetylcysteine (NAC) with oral rabeprazole
Number of subjects: 0
Study 31848062 — intervention group
Group type: COMPARATOR
Intervention: Oral rabeprazole
Number of subjects: 0
Study 31618774 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-profile threaded ESF pins placed without predrilling
Number of subjects: 20
Study 31618774 — intervention group
Group type: COMPARATOR
Intervention: Positive-profile threaded ESF pins placed with predrilling
Number of subjects: 20
Study 30137481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 100
Study 27114389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 27114389 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 27114389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) during year 1
Number of subjects: 5145
Study 27114389 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin users in ILI
Number of subjects: 5145
Study 27114389 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin users in ILI
Number of subjects: 5145
Study 27114389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) participants in upper 50% of weight loss
Number of subjects: 5145
Study 27114389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) participants in lower 50% of weight loss
Number of subjects: 5145
Study 25081493 — intervention group
Group type: EXPERIMENTAL
Intervention: RandAL method for aligning DNA sequences to reference genomes
Number of subjects: 0
Study 22735384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily, orally)
Number of subjects: 250
Study 22735384 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m(2) intravenously every 3 weeks)
Number of subjects: 250
Study 22735384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 250
Study 22735384 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 250
Study 20721651 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic bacterial formulation (90 billion CFUs/day)
Number of subjects: 46
Study 18796263 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (fundoplication)
Number of subjects: 810
Study 18796263 — intervention group
Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 810
Study 15629973 — intervention group
Group type: EXPERIMENTAL
Intervention: Infloran (Lactobacillus acidophilus and Bifidobacterium infantis) with breast milk twice daily until discharged
Number of subjects: 367
Study 15629973 — intervention group
Group type: COMPARATOR
Intervention: Breast milk alone
Number of subjects: 367
Study 11956264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential biochemotherapy (CVD + interleukin‐2 + interferon alfa‐2b)
Number of subjects: 190
Study 11956264 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CVD)
Number of subjects: 190
Study 11956264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential biochemotherapy
Number of subjects: 190
Study 11956264 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 190
Study 9607475 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and urokinase (5,000 U boluses at 12 and 24 hours)
Number of subjects: 63
Study 9607475 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 63
Study 9607475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 63
Study 8537865 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane plus DFDBA
Number of subjects: 10
Study 8537865 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane only
Number of subjects: 10
Study 8537865 — intervention group
Group type: COMPARATOR
Intervention: Comparison between test and control groups
Number of subjects: 10
Study 2375296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (14 g/d, 55% n-3 fatty acids)
Number of subjects: 64
Study 704653 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine 15 mg
Number of subjects: 8
Study 704653 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine 5-20 mg
Number of subjects: 8
Study 704653 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 8
Study 31382299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 98
Study 31382299 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 98
Study 31382299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 98
Study 31382299 — intervention group
Group type: COMPARATOR
Intervention: All steroids
Number of subjects: 98
Study 30990367 — intervention group
Group type: COMPARATOR
Intervention: IMRRP-2 (2-minute inter maximal-repetition rest period)
Number of subjects: 9
Study 30990367 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRRP-3 (3-minute inter maximal-repetition rest period)
Number of subjects: 9
Study 29106311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihormonal bionic pancreas (BP)
Number of subjects: 39
Study 29106311 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 39
Study 24557411 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) approach
Number of subjects: 90
Study 24557411 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (anterolateral modified Watson‐Jones)
Number of subjects: 90
Study 23635331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone self-management support intervention
Number of subjects: 480
Study 23635331 — intervention group
Group type: COMPARATOR
Intervention: Usual care in the existing programme
Number of subjects: 480
Study 22137078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyn TMP 2/3
Number of subjects: 3267
Study 22137078 — intervention group
Group type: EXPERIMENTAL
Intervention: Den TMP 2/3
Number of subjects: 3267
Study 22137078 — intervention group
Group type: COMPARATOR
Intervention: TMP 0/1
Number of subjects: 3267
Study 18203683 — intervention group
Group type: COMPARATOR
Intervention: School-based HIV prevention programme (control arm of a cluster-randomized controlled trial)
Number of subjects: 2360
Study 17116511 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing norgestimate (NGM) 180-250 microg and ethinyl estradiol (EE) 35 microg
Number of subjects: 112